Skip to main content
Ind-Swift Laboratories Ltd. logo

Ind-Swift Laboratories Ltd. — Investor Relations & Filings

Ticker · INDSWFTLAB ISIN · INE915B01019 LEI · 335800ZT8UFD9Y8ZMP56 BSE.NS Manufacturing
Open in API
Filings indexed 809 across all filing types
Latest filing 2025-07-31 Capital/Financing Update
Country IN India
Listing BSE.NS INDSWFTLAB

About Ind-Swift Laboratories Ltd.

https://www.indswiftlabs.com

Ind-Swift Laboratories Ltd. is a global manufacturer specializing in Active Pharmaceutical Ingredients (APIs) and Advanced Intermediates. The company focuses on research and development, process chemistry, and large-scale production across diverse therapeutic segments, including macrolide antibiotics, cardiovascular agents, antihistamines, antidiabetics, and antipsychotics. Operating multiple manufacturing facilities that adhere to international regulatory standards such as USFDA, EDQM, and PMDA, the organization provides high-quality chemical entities to the global market. Its core competencies lie in complex chemical synthesis and the development of cost-effective manufacturing processes for generic and specialty drug substances. The company maintains a strong emphasis on quality assurance and regulatory compliance to support its extensive portfolio of products distributed worldwide.

Recent filings

Filing Released Lang Actions
Scheme of Arrangement
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges (BSE and NSE) regarding the approval and sanction of a Scheme of Arrangement for Amalgamation between two companies, Ind-Swift Limited and Ind-Swift Laboratories Limited. It details the receipt of the NCLT order sanctioning the scheme, the appointed date, effective date, record date for share allotment, and amendment to the Memorandum of Association including increase in authorized share capital. The document is a regulatory announcement about corporate restructuring and capital changes, not a full report or financial statement. It is not an annual or interim report, earnings release, or audit report. It is also not a proxy, voting result, or remuneration report. The key elements are related to corporate actions and capital structure changes. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive information about capital changes and amalgamation, so it is not merely a report publication announcement or regulatory filing. Confidence is high due to clear references to capital increase and amalgamation effective dates.
2025-07-31 English
Amalgamation/Merger
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding an update on the Scheme of Arrangement for Amalgamation between two companies. It references regulatory compliance under SEBI Listing Regulations and mentions receipt of a certified copy of the final order from the National Company Law Tribunal approving the scheme. The document is short (1981 characters) and primarily serves as an announcement of a regulatory event (approval of a merger scheme) rather than the merger documents themselves. It does not contain detailed merger filings or financial data but informs the exchanges and public about the approval status. This fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories. It is not a full merger filing (MA or TAR), nor a report publication announcement (RPA) since it is not announcing a report release but a regulatory event update.
2025-07-28 English
General Updates
Regulatory Filings
2025-07-25 English
General Updates
Regulatory Filings
2025-07-25 English
Conversion
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (BSE and NSE) regarding the outcome of a Preferential Issue Committee meeting of the Board of Directors. It details the allotment of equity shares pursuant to the conversion of fully convertible warrants, including the number of shares allotted, the issue price, and the resulting increase in paid-up equity share capital. The document references compliance with SEBI regulations and includes an annexure with detailed disclosures about the preferential allotment. The content focuses on a capital raising event through preferential allotment and share issuance, not a full financial report or earnings announcement. The document length is 4617 characters, which is sufficient to contain substantive information about the capital issuance. Therefore, the document fits the category of Capital/Financing Update (CAP).
2025-07-22 English
Scheme of Arrangement
Regulatory Filings Classification · 95% confidence The document is an official communication addressed to stock exchanges regarding the sanctioning of a Scheme of Arrangement for Amalgamation by the National Company Law Tribunal (NCLT). It references the approval order dated July 17, 2025, and mentions that the certified copy of the order is awaited. The content focuses on the regulatory approval and procedural update of a merger/amalgamation scheme, not the merger filing itself or detailed merger documents. It is an announcement of a regulatory event related to M&A activity but does not contain merger proxy statements or tender offer filings. Given the nature of the document as an official intimation under SEBI regulations about the sanctioning order, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a full M&A filing or merger communication. The document length is short and it is an announcement rather than a full report or detailed filing.
2025-07-17 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.